Your assumptions are wrong. I am not a nurse. Iatrogenic pneumothorax IS a reportable sentinel event [in the US] thats why we review each and every case. AHRQ tracks institutions rates and benchmarks them annually by region and nationally. We perform most of our staging for lung CA by EBUS and mediastinoscopy, not IR. So although the relative rate of pneumothax assoc with lung bx may be higher, we only see 1 or 2 of these a year. We easily see that many per quarter from liver bx. Otherwise, I think we can agree there needs to be a more compelling reason than gathering trial data to subject pts to this.
Market Data 
Markets 
AI
